Avatrombopag Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of avatrombopag during breastfeeding. The manufacturer recommends avoiding breastfeeding during the use of avatrombopag and for at least 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Avatrombopag
CAS Registry Number
570406-98-3
Drug Class
Breast Feeding
Lactation
Receptors, Thrombopoietin
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
